<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04940520</url>
  </required_header>
  <id_info>
    <org_study_id>Onicomicose</org_study_id>
    <nct_id>NCT04940520</nct_id>
  </id_info>
  <brief_title>Alpha-bisabolol for Onychomycosis Treatment</brief_title>
  <official_title>Alpha-bisabolol for Onychomycosis Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidade do Vale do Sapucai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidade do Vale do Sapucai</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical, interventional, longitudinal study with random sampling. 60 patients will be&#xD;
      divided into three groups, group A: control group, drug recommended by the Brazilian Society&#xD;
      of Dermatology, group B: alpha bisabolol-based product associated with low-level laser&#xD;
      therapy, and group C: alpha bisabolol based product. The topical application will be&#xD;
      performed twice a day, while the laser application and photographs of the lesions, every 15&#xD;
      days. Areas of the lesions will be compared.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Introduction: Onychomycosis is an infection caused by fungi that feed on keratin, a protein&#xD;
      that makes up most of the nails. In patients with diabetes mellitus and onychomycosis, the&#xD;
      risk of foot complications is a concern, especially for those who do not perform the practice&#xD;
      of self-care of the skin, nails and feet in general correctly, which can trigger an important&#xD;
      tissue damage that culminates in limb amputation. One of the alternatives for the treatment&#xD;
      are herbal medicines. The application of alpha-bisabolol in the pharmaceutical sector is&#xD;
      related to its anti-inflammatory, antispasmodic, antiallergic, drug permeation and deworming&#xD;
      properties, having an important action in the morphology of dermatophytic fungal cells.&#xD;
      Objectives: Develop and evaluate a pharmaceutical formula with alpha-bisololol for the&#xD;
      treatment of onychomycosis. Methods: Clinical, interventional, longitudinal study with random&#xD;
      sampling. The study will be held at the Sthomatherapy Clinic of the Nursing Care and Teaching&#xD;
      Center at the Samuel Libânio Hospital and at the DermatoCare Clinic Stomatherapy and Podiatry&#xD;
      Clinic, Pouso Alegre, MG. 60 patients with onychomycosis will participate in this study,&#xD;
      which will be divided into three groups, group A: control group, drug recommended by the&#xD;
      Brazilian Society of Dermatology, group B: alpha bisabolol-based product associated with&#xD;
      low-level laser therapy, and group C: alpha bisabolol based product. The topical application&#xD;
      will be performed twice a day, while the laser application and photographs of the lesions,&#xD;
      every 15 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2020</start_date>
  <completion_date type="Actual">May 1, 2021</completion_date>
  <primary_completion_date type="Actual">November 30, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Injury area analysis</measure>
    <time_frame>2 months</time_frame>
    <description>All participants will have their nails photographed every 15 days for treatment control and evolution. Theses areas will be compared using the Image J program.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Onychomycosis</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group A: control group, drug recommended by the Brazilian Society of Dermatology</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alpha-bisabolol and laser</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group B: alpha bisabolol-based product associated with low-level laser therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alpha bisabolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group C: alpha bisabolol based product</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Drug recommended by the Brazilian Society of Dermatology</intervention_name>
    <description>Using a drug recommended by the Brazilian Society of Dermatology, twice a day.</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Alpha bisabolol product and laser</intervention_name>
    <description>Using alpha bisabolol-based product associated with low-level laser therapy. Alpha bisabolol-based product will be used twice a day, and laser therapy used once every fortnight.</description>
    <arm_group_label>Alpha-bisabolol and laser</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Alpha bisabolol product</intervention_name>
    <description>Using alpha bisabolol-based product twice a day</description>
    <arm_group_label>Alpha bisabolol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Volunteers with onychomycosis,&#xD;
&#xD;
          -  aged over 18 years.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Volunteers have a known allergic process to topical treatment, and those who present&#xD;
             an allergic reaction to alpha bisabolol&#xD;
&#xD;
          -  patients with a history of neoplasm in a location close to the nail plate, and&#xD;
             patients with psoriasis.&#xD;
&#xD;
          -  Volunteers who withdraw their consent at any time during the research, and those who&#xD;
             present an allergic reaction to alpha bisabolol&#xD;
&#xD;
          -  Pregnant women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adriana R dos Anjos Mendonça, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vale do Sapucaí University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vale do Sapucaí University</name>
      <address>
        <city>Pouso Alegre</city>
        <state>Minas Gerais</state>
        <zip>37550-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 17, 2021</study_first_submitted>
  <study_first_submitted_qc>June 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 25, 2021</study_first_posted>
  <last_update_submitted>June 25, 2021</last_update_submitted>
  <last_update_submitted_qc>June 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidade do Vale do Sapucai</investigator_affiliation>
    <investigator_full_name>Adriana Rodrigues dos Anjos Mendonça</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Onychomycosis</keyword>
  <keyword>Phytotherapy</keyword>
  <keyword>Laser Therapy</keyword>
  <keyword>Plant Oils</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Onychomycosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

